<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epstein-Barr virus (EBV) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and latency has been associated with <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, including nasopharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp> and Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>EBV encoded latent membrane protein 2A (LMP2A) is expressed in most EBV-associated <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> and as such provides a therapeutic target </plain></SENT>
<SENT sid="2" pm="."><plain>Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is a <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematopoietic cancer</z:e> associated with the translocation of c-MYC to one of the immunoglobulin gene promoters leading to abnormally high expression of MYC and development of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Our laboratory has developed a murine model of EBV-associated Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> by crossing LMP2A transgenic mice with MYC transgenic mice </plain></SENT>
<SENT sid="4" pm="."><plain>Since LMP2A has been shown to activate the PI3K/Akt/mTOR pathway, we tested the therapeutic efficacy of mTOR inhibitor <z:chebi fb="0" ids="9168">rapamycin</z:chebi> on the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and <z:hpo ids='HP_0001744'>splenomegaly</z:hpo> in these double transgenic mice (Tg6/λ-MYC) </plain></SENT>
<SENT sid="5" pm="."><plain>We found that <z:chebi fb="0" ids="9168">rapamycin</z:chebi> reversed <z:hpo ids='HP_0001744'>splenomegaly</z:hpo> in Tg6/λ-MYC mice prior to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> formation by targeting B cells </plain></SENT>
<SENT sid="6" pm="."><plain>In a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> transfer model, we also found that <z:chebi fb="0" ids="9168">rapamycin</z:chebi> significantly decreased <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e>, <z:hpo ids='HP_0001744'>splenomegaly</z:hpo>, and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells in the bone marrow of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> recipients </plain></SENT>
<SENT sid="7" pm="."><plain>Our data show that <z:chebi fb="0" ids="9168">rapamycin</z:chebi> may be a valuable candidate for the development of a treatment modality for EBV-positive <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, such as Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and more importantly, provides a basis to develop inhibitors that specifically target <z:mp ids='MP_0001799'>viral</z:mp> gene function in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells that depend on LMP2A signaling for survival and/or growth </plain></SENT>
</text></document>